PubMed Health⌕ Search

Biomedical subjects

K B Lim

Publications and source records attributed to K B Lim.

68 records · Page 4Linked to original sources
PubMed1985

The microbiology of non-gonococcal urethritis (NGU) in Singapore.

Ninety-six men with non-gonococcal urethritis (NGU) were studied to determine the microbiology of NGU in Singapore. Chlamydia trachomatis emerged as the most common aetiologic agent, being isolated in 29 (30.2%) of 96 patients. The recovery rate of other potential pathogens and their significance locally are discussed.

Chlamydia Infections↗
PubMed1984

Treatment of uncomplicated gonorrhoea with rosoxacin (acrosoxacin).

An open study was designed primarily to evaluate the efficacy of rosoxacin in the treatment of gonorrhoea caused by penicillinase producing Neisseria gonorrhoeae (PPNG) and non-PPNG strains. A total of 199 patients (99 men and 100 women) satisfactorily completed follow up examinations, 50 men and 50 women having received rosoxacin 300 mg orally and the remainder having received kanamycin 2 g intramuscularly. Rosoxacin achieved an overall cure rate of 94% (96.7% for PPNG and 90% for non-PPNG strains). In patients treated with kanamycin the overall cure rate was 89.9% (92.7% for PPNG and 83.3% for non-PPNG strains). A correlation between treatment failures and minimum inhibitory concentrations (MICs) of rosoxacin was noted in non-PPNG strains but not in PPNG strains. Side effects which were mild and self limiting were noted in 15 of 100 patients treated with rosoxacin. The high failure rates associated with non-PPNG strains requiring MICs of 0.125 mg/l and the observation of a substantial rise in the MICs for isolates after treatment is of concern. Otherwise, rosoxacin in a single dose of 300 mg appears to be safe and effective for the treatment of uncomplicated gonorrhoea.

4-Quinolones↗
PubMed1984

Two dose Augmentin treatment of acute gonorrhoea in men.

We studied 192 men with acute gonococcal urethritis, 97 of whom received two oral doses of Augmentin (amoxycillin 3 g and clavulanic acid 250 mg) separated by a four hour interval; the remaining 95 received 2 g kanamycin in a single intramuscular injection. Of the patients treated with Augmentin, 93 (95.9%) were cured, which was significantly more than the 83 (87.4%) patients treated with kanamycin. Augmentin was equally effective in the treatment of penicillinase producing Neisseria gonorrhoeae (PPNG) and non-PPNG infections, the cure rates for which were 96.6% and 95.6% respectively.

Acute Disease↗
PubMed1983

Periurethral Teflon injection: a simple treatment for urinary incontinence.

The follow-up of 28 patients with urinary incontinence treated with periurethral Teflon injection revealed significant improvement in 53.6% and complete cure in 21.4%. Patients most likely to benefit were those with weak sphincters and stable detrusors. The method is quick and safe and requires only a brief hospital stay. It is suitable for patients in whom conventional operative techniques have failed or in whom surgery is best avoided on medical grounds.

Adult↗
PubMed1983

Drugs in pregnancy.

Explore the source record for details and available documents.

Alcohol Drinking↗
PubMedDate not supplied

Ceftriaxone for treatment of primary syphilis in men: a preliminary study.

Eighteen male patients with primary syphilis were randomly assigned to one of the following treatment schedules: ceftriaxone (3 g in a single intramuscular [im] injection), ceftriaxone (2 g im daily for two days), ceftriaxone (2 g im daily for five days), and benzathine penicillin (2.4 X 10(6) units in a single im injection). The single 3-g dose of ceftriaxone cured three men, one had a sustained response, and one failed to be cured. Of the patients given 2 g of ceftriaxone im daily for two days, three were cured and two had a sustained response. All three men treated with 2 g of ceftriaxone daily for five days had a sustained response. In the group given penicillin, three men were cured, one had a sustained response, and one was lost to follow-up.

Adolescent↗
PubMedDate not supplied

Comparison between high and low molecular weight hyaluronates in knee osteoarthritis patients: open-label, randomized, multicentre clinical trial.

Efficacy and safety of high and low molecular weight hyaluronates in knee osteoarthritis patients were compared in a randomized, open-label trial. Patients in the high molecular weight hyaluronate group were treated once weekly for 3 weeks and in the low molecular weight group once weekly for 5 weeks. We evaluated weight-bearing pain, degree of flexion, swelling and knee tenderness; frequency and amount of rescue medication; patient and investigator global assessment of pain, and safety over 12 weeks after final injection of study medication. Significant improvements in pain and WOMAC-Likert scores were observed in both groups, but not between groups. Knee joint pain improvement was noted in both groups by patients and investigators during follow-up. Close correlation was observed between patient- and investigator-reported data. There was no significant difference in side-effects between the groups. In conclusion, the efficacy and safety of high and low molecular weight hyaluronate are similar.

Adjuvants, Immunologic↗